SCHEMBL22749305

SCHEMBL22749305

CSc1nccc(C2(N)CCOCC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.32
▸ MAPK13 O15264 1/20 0.32
▸ MAPK12 P53778 1/20 0.32
▸ MAPK11 Q15759 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ POLB P06746 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ PLK4 O00444 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29368124 0.98 LMNA (0.35) LMNAGAAALDH1A1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL28701070 0.98 LMNA (0.35) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL22762634 0.78 LMNA (0.36) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL21392085 0.78 FFAR4 (0.35) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL22758556 0.77 FFAR4 (0.39) LMNAGAAALDH1A1MAPTSMN1; SMN2
Lithium SCHEMBL30725900 0.76 FFAR4 (0.38) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL29142075 0.76 FFAR4 (0.38) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL28682801 0.76 FFAR4 (0.36) LMNAGAAALDH1A1MAPTSMN1; SMN2
Lithium Ion SCHEMBL22749301 0.75 FFAR4 (0.35) LMNAGAAALDH1A1MAPTSMN1; SMN2
SCHEMBL21392151 0.74 FFAR4 (0.37) ALDH1A1FFAR4MAPK14HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114008039-B Compounds as human CTPS1 inhibitors for the treatment of proliferative diseases 斯泰普制药股份公司 2024-01-16 — — CN disclosed
CN-114008039-A N- (5- (6-ethoxypyrazin-2-yl) pyridin-2-yl) -4- (2- (methylsulfonylamino) pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases 斯泰普制药股份公司 2022-02-01 — — CN disclosed
WO-2020245664-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 — — WO disclosed
WO-2020245664-A1 N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES STEP PHARMA S.A.S. (FR) 2020-12-10 — — WO disclosed
Send feedback